Collaboration underscores both companies’ commitment to advancing patient-centric solutions and expanding access to therapies through novel drug delivery technologies Under the terms of the agreement, ...
CINCINNATI, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse ® on-body drug delivery system, announced ...
Subcutaneous Sarclisa, administered via OBDS, showed non-inferior efficacy to IV Sarclisa in relapsed/refractory multiple myeloma patients. The IRAKLIA study enrolled 532 patients globally, ...
The MarketWatch News Department was not involved in the creation of this content. Enable Injections Announces Agreement with Sobi(R) to Develop and Distribute Aspaveli(R) in Combination with enFuse(R) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results